Kornimate/medical-research-clean huggingface dataset:
non-invasive chromosomal evaluation of 22q11.2

Conditions: 22q.11.2 Deletion/Duplication

Summary: this study is being conducted to develop and evaluate a cell-free fetal dna test (harmony) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication.


Eligibility criteria:
inclusion criteria: 1. patient is ≥18 years of age and able to provide consent or, if under the age of 18, the patient has parental consent and child assent provided as required by the governing ethics committee. 2. if pregnant, patients must have a singleton pregnancy and be at least 10 weeks gestation at the time of the study blood draw. 3. patients must meet at least one of the following conditions at the time of enrollment: 1. are pregnant with abnormal fetal cardiac findings on ultrasound and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period; 2. are pregnant with fetal ultrasound findings consistent with a 22q11.2 deletion/duplication phenotype and is undergoing evaluation with prenatal genetic testing or planned post-natal genetic testing in the immediate newborn period; 3. are pregnant with a fetus known to have a 22q11.2 deletion/duplication confirmed by genetic testing with documentation is available; 4. are biologically related parent of an enrolled child has chromosomal deletion/duplication in the region of 22q11.2; 4. if the site is selected to enroll control patients, they must be pregnant women undergoing prenatal genetic evaluation for 22q11.2 deletion/duplication. exclusion criteria patients meeting any of the following criteria will be excluded from the study: 1. patient has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant.

Keywords: velocardiofacial syndrome shprintzen syndrome conotruncal defects chromosomal abnormalities 22q, 22q.11.2 deletion duplication
metolazone as early add on therapy for acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: the primary objective of the study is to determine efficacy of metolazone as synergistic therapy with lasix in patients with acute decompensated heart failure. this will be a multicenter double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure.

as described by the principal investigator (dr. heywood): the primary objective of the study is to determine efficacy of metolazone as synergistic therapy with lasix in patients with acute decompensated heart failure. this will be a multicenter double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure.

Eligibility criteria:
inclusion criteria: * subject is 18 years of age at time of enrollment. * admitted with acute decompensated heart failure based on history, physical exam, and laboratory parameters, must include both: 1. at least 1 symptom of either dyspnea, orthopnea, or edema. 2. at least 1 sign of rales on auscultation, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography. * be willing to comply with protocol-specified instructions * able to understand and grant informed consent. exclusion criteria: * inability to give informed consent. * systolic bp \< 90 mmhg * creatinine clearance less than 20ml/min or creatinine greater than 2.5mg/dl. * serum sodium less than 128meq/l, potassium levels less than 3.5meq/l * known adverse reaction to metolazone * inability to take oral medications * severe aortic stenosis (ava \< 0.8cm³) * history of hypertrophic obstructive cardiomyopathy. * metastatic carcinoma * severe chronic obstructive pulmonary disease (copd), fev \< 1l * severe dyspnea requiring prolonged cpap or intubation * moderate/severe dementia
low-dose il-2 in established t1d - the "proreg" study

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes, Autoimmune

Summary: randomized, controlled, double-blinded, multicenter, phase i/ii clinical trial to evaluate the safety of low-dose il-2 and determine whether low-dose il-2 therapy for one year, can prevent further loss of beta-cell function in patients with established t1d, (primary outcome). the study will carefully examine various effects of low-dose il-2 on the immune system in patients with t1d, including effects on treg and other cell subsets, and disease-specific autoimmune responses.

randomized, controlled, double-blinded, multicenter, phase i/ii clinical trial to evaluate the safety of low-dose il-2 and determine whether low-dose il-2 therapy for one year, can prevent further loss of beta-cell function in patients with established t1d, (primary outcome). the study will carefully examine various effects of low-dose il-2 on the immune system in patients with t1d, including effects on treg and other cell subsets, and disease-specific autoimmune responses. patients will be treated with ilt-101 or placebo. ilt-101 will be given at doses of 0.5 million iu (body surface area \ 2 m2), via subcutaneous (s.c.) injections. patients will receive a course of 5 daily injections (days 1-5. starting on day 15, patients will receive an s.c. injection (same dose) every 15 days for 1 year. thus, patients will receive 29 injections during the first year of treatment. at the end of the first year, approximately half of those randomized to ilt-101 will continue receiving treatment every 15 days, until the end of the second year (23 doses). the other half will stop therapy and will be switched to a placebo. a group of patients will be randomly assigned to a placebo for the duration of the study. patients to be included in this study are those diagnosed with t1d who would have had t1d from 4 months to 1 year at the time of randomization, who have a current or past demonstration of autoimmunity (using autoantibodies), and maintain preserved β-cell function, defined as an mmtt stimulated c-peptide \>0.2 nmol/l. this population is chosen because it will extend the scope of therapy beyond the immediate time following diagnosis when most previous studies of immunotherapy in t1d have been conducted. this trial can further impact the field if a therapeutic benefit is shown when the disease is more established.

Eligibility criteria:
inclusion criteria: * 8-21 years of age * t1d, demonstrated by at least one islet autoantibody * t1d duration 4-12 months at the time of the first dose * peak stimulated c-peptide \>0.2 nmol/l during a 4-hour mmtt exclusion criteria: * treatment with oral anti-diabetic agents * illnesses that would preclude use of low-dose il-2

Keywords: diabetes type 1 diabetes autoimmune diabetes, autoimmune interleukin-2 interleukin il-2
early versus standard endoscopic interventions for peripancreatic fluid collections

Conditions: Acute Pancreatitis; Peripancreatic Fluid Collections; Endoscopic Ultrasound-Guided Drainage; Pancreatic Fluid Collections

Summary: acute pancreatitis is a complex gastrointestinal disease with a variable course that is often difficult to predict early in its development. the majority of cases are mild, self-limited, and follow an uncomplicated course. however, 10-20% of cases can be associated with pancreatic or peripancreatic fluid collections, or both. infected necrosis complicates 10% of all acute pancreatitis episodes and is associated with a mortality of 15-20%. current guidelines for necrotizing pancreatitis recommend to postpone drainage until 4 or more weeks after initial presentation to allow collections to "walled-off". however, evidence of infection with clinical deterioration despite maximum support may mandate earlier intervention. it is unclear whether such delay is needed for drainage or whether earlier endoscopic intervention could actually be beneficial in the current approach. the aims of this randomized, controlled, multicenter study is to evaluate whether early endoscopic drainage in patients with peripancreatic fluid collection is superior to postponed intervention in the current practice.

eus guided drainage is now the preferred route for peripancreatic fluid collections (pfc). it belongs to transmural drainage and is accomplished by creating a fistula and placing a stent between the gastric or duodenal lumen and the pfc. the size of the pfc and percentage of solid debris were noted prior to puncture, and the optimal site of transluminal puncture was identified using eus. participants will be randomly allocated to either the intervention or the control group. participants in the intervention group will undergo eus guided drainage earlier (≤1 weeks) in the disease course. the follow-up duration is 6 months from randomization. all patients undergo imaging (contrast enhanced computed tomography) at 3- and 6-months post randomization.

Eligibility criteria:
inclusion criteria: * adult patients with pfc; * all patients with pfc will be screened for eligibility including a protocolized approach; * patients admitted within 72 hours of onset exclusion criteria: * more than 30 days after onset of acute pancreatitis * pregnant women * documented chronic pancreatitis * inability to gave informed consent

Keywords: acute pancreatitis peripancreatic fluid collections endoscopic ultrasound endoscopic drainage
comparison of inflammatory factors, pain scale, and postoperative recovery quality (qor - 15) in patients undergoing colorectal cancer surgery with conventional general anesthesia techniques compared to general anesthesia combined with epidural anesthesia at prof. ngoerah hospital

Conditions: Inflammation Biomarkers; Quality of Recovery (QoR-15); Visual Analog Pain Scale

Summary: surgery can increase il-6 cytokines, triggering inflammation and metastasis. the combination of general and epidural anesthesia has the potential to suppress il-6, improve the tumor microenvironment, provide analgesia, and enhance postoperative recovery. objectives :to compare the effectiveness of postoperative analgesia quality in colorectal cancer patients receiving general anesthesia combined with epidural anesthesia.

patients will be divided into 2 groups: group p (treatment) and group k (control). before anesthesia, 2-3 ml of blood will be collected by the researcher from patients in both groups using a red tube. patients in the control group will undergo conventional general anesthesia. patients in the treatment group will undergo conventional general anesthesia combined with epidural anesthesia. patients will be administered 0.25% bupivacaine local anesthetic incrementally until the desired volume is achieved based on the targeted segmental block height. six hours postoperatively, 2-3 ml of blood will be collected, vas (visual analog scale) will be assessed 24 hours postoperatively, and qor-15 (quality of recovery-15) will be evaluated postoperatively.

Eligibility criteria:
inclusion criteria: * patients aged 18 - 65 years * patients with asa physical status i - iii exclusion criteria: * patients with contraindications to regional anesthesia * patients with mental disorders or psychiatric disorders * the patient has a history of allergy to the local anesthetic used. * the patient or family refuses to take part in the study * bmi \> 30 kg/m2

Keywords: epidural anesthesia interleukin 6 postoperative pain colorectal cancer regional anesthesia quality of recovery-15
compensatory kinematic movements in various directions after stroke

Conditions: Cerebral Stroke; Hemiplegia, Spastic

Summary: this is cross-sectional study. by comparing kinematic analysis between stroke and healthy subjects in various directions, this investigation analyzes the compensatory kinematic movement for reaching task in stroke survivors

after institutional review board approval, it recruits 2 groups. one group is elderly and another group is stroke survivors. the stroke group that meets the criteria. another group is age matching of the stroke and not having an orthopedic or neurological disease. participants of all the groups are assessed for kinematic by motion capture during reaching arm(affected side; stroke group, non-dominant side; healthy group) in 3 directions(medial_45, forward_90 and lateral_135 degrees). retroreflective markers are placed on 11 anatomical place (3th metacarpal joint, both acromion, elbow lateral and medial epicondyle, lateral and medial styloid process, xyphoid process, sternum, c7, t4). participants reach to a bell as quickly as possible in three directions. the subject reach to a bell 5 times in each direction and assess clinical evaluation such as fugl meyer assessment, postural assessment scale, modified ashworth scale, shoulder-elbow range of motion and trunk instability scale.

Eligibility criteria:
inclusion criteria: the inclusion criteria used in the randomized controlled trials were as follows: stroke * subject consisted of the physician's confirmation of chronic hemiplegia * onset ≥ 6 months * mini-mental state examination≥25 * biceps ≤2, triceps≤2 * ability to sit on a chair alone * fma upper extremity score ≥ 21 points, fma upper extremity ≤ 66 points healthy * age of matching the stroke group * absence of neurological disease and orthopedic disease exclusion criteria: stroke * biceps\>2, triceps\>2 * flaccid * neglect syndrome * have neurological disease and orthopedic disease * lack of coordination

Keywords: chronic stroke reaching task motion capture
ethnicity data in hiv positive men who have sex with men

Conditions: HIV

Summary: are there differences between the way that non-white men who have sex with men living in london with hiv describe their own ethnicity and the way in which their ethnic group is recorded in nhs clinics? we aim to describe the way in which clinics in london currently record a patient's ethnic group. without accurate data for an individual's ethnic group we are unable to draw meaningful conclusions about their experiences of hiv care. it may be the case that patients from particular ethnic groups require specific ways of monitoring and treating their hiv but without knowing if these people are in a particular group any services directed to them may be wasted or underused.

hiv doctors will be identified at each of the london hiv treatment centres and details of the project will be communicated to them via email. these doctors will then be sent paper copies of the patient information sheets (pis), patient questionnaires and clinician questionnaires. eligible patients (i.e. men having sex with men with hiv from non-white ethnic groups) will be identified by their doctors and will be asked to read the pis and complete the questionnaire. this will be a single questionnaire and no follow up for the patient will be required. no personal information (e.g. date of birth, hospital number) will be recorded. eligible patients will be all those coming to clinic for hiv care between 1st june and 31st of july 2011. based on estimates from 2009 data held by the hpa, each doctor will on average be asked to recruit 30 patients over the two month period. the questionnaire will ask questions regarding self description of ethnicity, sexuality, parents' ethnicity, country of birth and other countries of residency (if relevant). it is anticipated that to read the pis and complete the questionnaire should take no longer than 15 minutes. the doctor will then return the paper questionnaire (in an addressed envelope supplied) to dr williams. dr williams will then bring together and analyse the data from the questionnaires and write up her findings for publication and presentation at a national conference.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hiv * male patients who have ever had sex with other men (bi- or homosexual to both be included) * patients of non-white ethnicity (patients described as being of "mixed" or "other" ethnicity are to be included) exclusion criteria: * female patients * male patients who have only ever had sex with women * patients whose ethnicity is described as "white" * patients unable to read or understand the written questionnaire

Keywords: hiv msm ethnicity
sonographic assessment and visualization of ectopics in emergency medicine

Conditions: Ectopic Pregnancy

Summary: observational study of the use of ultrasound by emergency physicians in the evaluation of patients at risk of ectopic pregnancy.

emergency physicians who have undergone training according to the american college of emergency physicians guidelines will be evaluated in the accuracy of performing pelvic ultrasounds among patients at risk for ectopic pregnancy.

Eligibility criteria:
inclusion criteria: * pregnant females in 1st trimester * present to emergency department * complaint of abdominal/pelvic pain or vaginal bleeding exclusion criteria: * previous ultrasound diagnostic of location of pregnancy

Keywords: bedside ultrasound
go team: glucose optimization through technology assisted management

Conditions: Type 1 Diabetes

Summary: black/african american children and young adults with type 1 diabetes are less likely to use diabetes technologies, such as continuous glucose monitors, insulin pumps, and automated insulin delivery systems, compared to white children and young adults. the investigators are working to find ways to make sure that all patients with type 1 diabetes are equally able to use these technologies. the purpose of this study is to find out if a new computer program for the diabetes team, along with a smartphone app (called glucosano) for patients/parents, as well as a community health worker, are accepted and used by black/african american patients and parents living with type 1 diabetes, and if this can help decrease racial disparities in the use of diabetes technologies.


Eligibility criteria:
inclusion criteria: * self-reported as non-hispanic black * clinical diagnosis of t1d requiring treatment with insulin at the time of consent * not currently (within the past 3 months) using an automated insulin delivery system \\ * willingness to wear a continuous glucose monitor for 10 days at 3 different time points, and willingness to consider use of a personal continuous glucose monitor exclusion criteria: * clinical diagnosis of type 2 or monogenic diabetes * completed high school * non-english speaking guardians * automated insulin delivery system use within the past 3 months * custody of children and family services

Keywords: pediatric diabetes technology disparities
visualized monitoring of fibrosis formation in heart failure with 68ga-fapi pet

Conditions: Heart Failure; Positron Emission Tomography

Summary: this is a diagnostic study. patients were included from patients with clinically suspected or confirmed heart failure, and 68ga-fapi and 13n-nh3 gated myocardial imaging were performed to evaluate the effectiveness of 68ga-fapi pet imaging in visualizing the degree of myocardial fibrosis in patients with heart failure. the subjects completed 68ga-fapi and 13n-nh3 gated myocardial imaging in a one-stop process, and collected general information, clinical data, echocardiography, blood routine, liver and kidney function indicators, 68ga-fapi and 13n-nh3 pet imaging results and other imaging data of the patients and volunteers.

fibroblast activated protein (fap) is a type ii membrane-bound glycoprotein that is highly specifically expressed in activated fibroblast reactions. the 68ga labeled fibroblast activated protein inhibitor (68 ga-fapi) has shown advantages of high uptake and high image contrast in imaging the activated fibroblast response, including its successful use in visualizing the degree of liver fibrosis. the molecular imaging probe targeting fap combined with the mature myocardial perfusion imaging agent 13n-nh3 can help us to achieve the following objectives: on the one hand, to investigate the myocardial fibrosis in patients with heart failure and to visualize the formation of fiber-activated protein in the process of heart failure; at the same time, the performance of 68ga-fapi in differential diagnosis of heart failure and grading of heart failure degree was discussed, so as to make up for the insufficiency of clinical routine imaging technology in the diagnosis of myocardial fibrosis in heart failure.

Eligibility criteria:
inclusion criteria: * adult patients (age 18 years or above), gender is not limited; * patients with clinically suspected or confirmed heart failure (supporting evidence includes visual examination, cardiac mri, cardiac ultrasound, and serological indicators, etc.), and patients who agree to undergo 68ga-fapi and 13n-nh3 imaging; * the patient or his legal representative can sign the informed consent. exclusion criteria: * acute systemic diseases and electrolyte disorders； * pregnant or lactating women； * patients refuse to sign the informed consent.
the future management of patients with neoplasms of the gastro-intestinal tract

Conditions: Pancreatic Adenocarcinoma; Cholangiocarcinoma; Colon Cancer

Summary: the aim of the present study is to research histological and molecular markers in patients with neoplasia of the gastrointestinal tract.

the aim of the present study is to search for histological and molecular markers in patients with neoplasia of the gastrointestinal tract.

Eligibility criteria:
inclusion criteria: * age 18 years or older; * ps ecog 0-2; * histological diagnosis of cancer of the gastro-enteric district: intestinal, pancreatic, biliary tract neoplasms; * radiological evidence of resectable/locally advanced/metastatic disease on the date of the first visit; * availability of tumour histological material; * at least one visit following the first oncological visit. exclusion criteria: * absence of histological diagnosis of neoplasm of the gastro-enteric tract; * lack of histological specimens on which to perform examinations.

Keywords: pancreatic cancer, bile duct cancer, colon cancer
a study to compare two different tablet formulations of azd8931 in healthy males and females

Conditions: Healthy

Summary: a study to compare two different tablet formulations of azd8931 in healthy males and females.


Eligibility criteria:
inclusion criteria: * male or female subjects aged 18 to 55 years * females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-child bearing potential * body mass index between 19 and 30 kg/m2 and weight at least 50 kg and no more than 100 kg * male subjects must be willing to use barrier methods of contraception * be willing and able to comply with study procedures, restrictions and requirements exclusion criteria: * history of any clinically significant disease or disorder * any clinically significant abnormalities at screening * use of any prescribed or non-prescribed medication within 2 weeks * receipt of another nce or participation in any other clinical trial within 3 months * subjects who have previously received azd8931

Keywords: phase i healthy male and non-fertile female volunteers bioavailability azd8931